OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Oncology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint?	63
The role of signaling lymphocyte activation molecule family receptors in hematologic malignancies	43
Treatments and challenges in advanced prostate cancer	42
Role of PSMA PET/CT in imaging and management of prostate cancer	36
Collecting information from all sarcoma reference cancer centres worldwide: achievement and next steps	30
Neurorehabilitation in brain tumours: evidences and suggestions for spreading of knowledge and research implementation	27
Content features and its implementation in novel app-based psycho-oncological interventions for cancer survivors: a narrative review	24
Editorial introductions	23
State of the art and upcoming trends in HER2-directed therapies in gastrointestinal malignancies	21
First and further-line multidisciplinary treatment of retroperitoneal sarcomas	21
Psycho-oncology interventions focusing on fatigue and sleep disturbances	20
Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy	19
Harnessing dendritic cells for innovative therapeutic cancer vaccines	19
Epigenetic dynamics of aging and cancer development: current concepts from studies mapping aging and cancer epigenomes	18
Progress in diagnosis and treatment of checkpoint inhibitor pneumonitis	17
Beyond ‘the good, the bad and the ugly’: let us put rectal cancer patients at the centre of the decision making	17
Biomarkers and immunotherapy: where are we?	15
Indications and technique of minimally invasive surgery in early-stage cervical cancer	15
State-of-the-art and trends in fibroblast growth factor receptor-directed therapies in gastro-intestinal malignancies	14
Editorial introductions	14
New hopes in relapsed refractory primary central nervous system lymphoma	13
Editorial introductions	13
Can we yet use tertiary lymphoid structures as predictive biomarkers for immunotherapy response in melanoma?	13
Safety of assisted reproductive techniques in gynecological cancer patients	13
Impact of sentinel node use in lymphedema formation among gynecologic cancer patients	12

How to prevent human papillomavirus-related oropharyngeal cancer?	12
Neoadjuvant and adjuvant approaches in gastroesophageal cancers	12
Local treatment in patients with hereditary breast cancer: decision-making process in low-, moderate-, high-penetrance pathogenic germline mutation carriers	12
Immunomodulation for hepatocellular carcinoma therapy: current challenges	11
Recent advances in precision medicine for acute myeloid leukemia	11
Enhancing proactive life-sustaining treatment preference documentation in advanced cancer care: barriers and recommendations	11
State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies	11
Dyadic psychosocial interventions for patients with cancer and their caregivers: an update	11
WHO 2021 and beyond: new types, molecular markers and tools for brain tumor classification	11
Editorial introductions	11
Melanoma with genetic alterations beyond the BRAF V600 mutation: management and new insights	11
Pregnancy-related hormonal changes and thyroid growth: do they have an impact on the higher incidence of differentiated thyroid cancer in women?	11
Editorial: Lung cancer: continuous progress in diagnosis and treatment	10
Controversies in central nervous system prophylaxis of high-risk diffuse large B-cell lymphoma	10
Circulating tumor DNA in breast cancer: a biomarker for patient selection	10
Antibody–drug conjugates in rare genitourinary tumors: review and perspectives	10
A meta-analysis of the efficacy and toxicity of tyrosine kinase inhibitors in treating patients with different types of thyroid cancer: how to choose drugs appropriately?	10
Lung cancer screening in never smokers	10
Liquid biopsy in brain tumors: moving on, slowly	10
Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker results	9
Editorial introductions	9
Current evidence of integrative oncology modalities for managing adverse effects and survivorship issues among adolescents and young adult (AYA) cancer patients and survivors	9
Interventions aiming to improve advance care planning uptake in oncology: a scoping review of recent randomized controlled trials	9
The changing landscape for patients with relapsed/refractory acute myeloid leukaemia	8
The 5T's of health disparities in multiple myeloma in Latin America	8
Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients	8
Machine learning applications and challenges in graft-versus-host disease: a scoping review	8
Desmoid tumors: who, when and how to treat?	8
A new comprehensive and stratified concept for supportive care in cancer patients	8
The role of genetic testing in prostate cancer screening, diagnosis, and treatment	8
Editorial introductions	8
Pathology and new insights in central nervous system lymphomas	8
How to become a Multinational Association of Supportive Care in Cancer-designated center of excellence in supportive care in cancer	8
Hybrid magnetic resonance and PET imaging for prostate cancer recurrence	8
Editorial introductions	7
Editorial introductions	7
Pathologic diagnosis of lung cancer – recent developments	7
Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results	7
The path to personalized treatment in advanced and metastatic biliary tract cancers: a review of new targeted therapies and immunotherapy	7
Mind the target: programmed death ligand 1 in oesophagogastric cancers	7
How to support parenting in patients with cancer and co-parents? From research to practice	7
Preclinical glioma models in neuro-oncology: enhancing translational research	7
Editorial introductions	7
State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies	7
Less is more in endometrial cancer (SLN, conservative treatment, radical hysterectomy, molecular classification)	7
Potential application of artificial intelligence in cancer therapy	7
Controversies on chemotherapy for early HR+/HER2− breast cancer: the role of anthracyclines and dose intensification	7
Advantages of robotic surgery in obese patients with endometrial cancer	7
Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations	7
Editorial introductions	6

Targeting cancer stem cell pathways for lung cancer therapy	6
Treatment of radiation-associated angiosarcoma	6
HER2-positive breast cancer: cotargeting to overcome treatment resistance	6
How to monitor the side effects of treatments in cancer patients	6
How to treat localized Hodgkin lymphoma?	6
Breast surgery after neoadjuvant therapy	6
When do I ask for a DNA methylation array for primary brain tumor diagnosis?	6
Cellular therapies in sarcoma and other solid tumors	6
Advances in the pathogenesis of FLT3-mutated acute myeloid leukemia and targeted treatments	6
HIV-related lymphomas	6
Immunotherapies in non-metastatic gastrointestinal cancers	6
Adjuvant and neoadjuvant approaches in pancreatic cancer	6
Sarcoma incidence worldwide: regional differences in histology and molecular subtypes	6
Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer	6
Question prompt lists to improve communication between cancer patients and healthcare professionals	6
Achievements of international rare cancers networks and consortia in the neuro-oncology field	6
Surgical treatment for clinical early-stage expansile and infiltrative mucinous ovarian cancer: can staging surgeries safely be omitted?	5
Preoperative immunotherapy for head and neck cancers: state of art	5
Modeling the management of patients with human epidermal growth factor receptor 2-positive breast cancer with liquid biopsy: the future of precision medicine	5
Richter transformation: biological insights, diagnostic challenges and emerging therapies	5
Targeting exon 20 insertion mutations in lung cancer	5
Doxorubicin combined with Trabectedin in systemic first-line M+/recurrent leiomyosarcoma patients	5
Molecular oncology: what is needed to speed access to innovative therapies in clinical research?	5
Polyamine metabolism in prostate cancer	5
Therapeutic cancer vaccination against telomerase: clinical developments in melanoma	5
Clinical management of brain tumors in pregnancy	5
Update on bi-specific monoclonal antibodies for blood cancers	5
Early Detection of Cancers in the Era of Precision Oncology	5
Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas	5
New trends in supportive care of head and neck cancers	5
Thymic malignancies: role of immunotherapy and novel approaches	5
Current status of phosphoinotiside-3 kinase inhibitors in blood cancers	5
Neoadjuvant immune checkpoint blockade enhances local and systemic tumor immunity in head and neck cancer	5
Endoscopic inguinal lymphadenectomy for vulvar cancer, is it feasible?	5
Are epigenetic-targeting approaches ready for prime time in neuroendocrine neoplasms?	5
Perioperative immunotherapy in nonsmall cell lung cancer	5
Immunotherapy of sarcomas with modified T cells	5